>Using a two-stage assay, the team identified a number of compounds that inhibited the enzymatic action of BoNT serotype A light chain (BoNT/A LC). All inhibitors were further verified by high-performance liquid chromatography. Finally, molecular modeling techniques were used to predict structural features that contribute to inhibitor binding and potency.
These techniques revealed a common pharmacophore--a "scaffold" upon which future therapeutics can be built. This pharmacophore will serve as a basis for directing future efforts to develop BoNT/A LC inhibitors with enhanced potency. Testing in cell culture will be followed by animal modeling once the most promising candidates have been identified.
Study collaborators were Sina Bavari, James J. Schmidt, and Robert G. Stafford of USAMRIID; Rick Gussio, Daniel W. Zaharevitz, Edward A. Sausville, Douglas J. Lane, Connor F. McGrath, Ann R. Hermone, Tam L. Nguyen, Rekha G. Panchal, and James C. Burnett of NCI; and Jonathan L. Vennerstrom of UNMC.
"This work is the result of a productive collaboration between federal and academic partners," said Colonel Erik A. Henchal, commander of USAMRIID. "These are the relationships that will, in the future, deliver the biodefense products the nation needs."
Page: 1 2 Related biology news :1
Contact: Caree Vander Linden
US Army Medical Research Institute of Infectious Diseases
. Small-molecule inhibitors of anthrax lethal factor identified2
. Chemical genetics identifies SARS inhibitors3
. COX-2 inhibitors and renal damage in obesity-related Type II diabetes4
. Researchers learn certain enzyme inhibitors may help in cancer therapy following initial procedures5
. Study offers new insights into angiogenesis inhibitors6
. COX-2 inhibitors may delay onset of breast cancer7
. Harvard Medical School researchers discover first in a new class of mitosis inhibitors8
. Rare childhood genetic syndrome identified9
. Newly identified master gene key in babys first breath10
. Key stimulator of colorectal cancer identified11
. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers